Invention Application
- Patent Title: PHARMACEUTICAL COMPOSITION FOR PREVENTING IN-STENT RESTENOSIS
-
Application No.: US17429215Application Date: 2020-02-07
-
Publication No.: US20220125850A1Publication Date: 2022-04-28
- Inventor: Osamu HONMOU , Masanori SASAKI , Yuko SASAKI , Shinichi OKA , Masahito NAKAZAKI , Rie MAEZAWA
- Applicant: Sapporo Medical University , Nipro Corporation
- Applicant Address: JP Chuo-ku, Sapporo-shi, Hokkaido; JP Kita-ku, Osaka-shi, Osaka
- Assignee: Sapporo Medical University,Nipro Corporation
- Current Assignee: Sapporo Medical University,Nipro Corporation
- Current Assignee Address: JP Chuo-ku, Sapporo-shi, Hokkaido; JP Kita-ku, Osaka-shi, Osaka
- Priority: JP2019-020707 20190207
- International Application: PCT/JP2020/004698 WO 20200207
- Main IPC: A61K35/28
- IPC: A61K35/28 ; A61P9/10
Abstract:
The present invention relates to a pharmaceutical composition containing mesenchymal stem cells administered to a patient subjected to stenting. The present invention relates specifically to: a pharmaceutical composition for repairing and regenerating tissue, comprising mesenchymal stem cells, wherein the pharmaceutical composition is administered to a patient subjected to stenting; and the prevention of in-stent neointimal hyperplasia or in-stent restenosis with the pharmaceutical composition.
Information query
IPC分类:
